Mensifem

Cimicifuga racemosa dry extract, the active ingredient in Mensifem, is a herbal presented as an oral dry extract for oral use. It is derived from the rhizome of black cohosh, standardized to a 5‑10:1 ratio, and is marketed in the EU to help alleviate menopausal symptoms in women experiencing the transition to menopause.

GNH USA supplies Mensifem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Mensifem, an herbal preparation containing black cohosh dry extract, is used to manage symptoms associated with menopause. - Hot flashes: reduction in frequency and intensity of vasomotor episodes - Night sweats: decreased nocturnal sweating - Mood swings: improvement in emotional stability during menopause

Adverse reactions reported with black cohosh extracts are generally mild and reversible.

Common Side Effects: - Gastrointestinal upset: mild nausea or abdominal discomfort - Headache: transient mild to moderate headache episodes - Dizziness: occasional light‑headedness, especially on standing

Serious or Rare Side Effects: - Liver enzyme elevation: rare cases of hepatic dysfunction - Severe allergic reaction: anaphylaxis or angioedema - Hypotension: uncommon drops in blood pressure leading to faintness

Before using Mensifem, consider the following safety measures. - Pregnancy: avoid use during pregnancy unless advised by a healthcare professional - Breastfeeding: not recommended for nursing mothers without medical guidance - Liver disease: use with caution in patients with hepatic impairment - Drug interactions: review all concomitant medications for potential interactions - Monitoring: observe for signs of allergic reaction or unusual symptoms - Store at ambient temperature: keep in the original pack, protect from moisture and light

Mensifem may interact with other medicines; awareness of potential interactions helps ensure safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding - Hormone replacement therapy: possible additive estrogenic effects - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal irritation - Diuretics: possible alteration of electrolyte balance - Other herbal supplements with estrogenic activity: additive hormonal effects